Results from an international, multicenter phase 2 clinical trial led by Dr. Kenneth Ataga were published online by the New England Journal of Medicine on December 3 and were presented December 4 at the annual meeting of the American Society of Hematology in San Diego. The trial found that an investigational compound called SeIG1 dramatically reduces sickle cell pain crises.